摘要
靶向程序性死亡蛋白-1及其配体(PD-1/PD-L1)的免疫抑制剂是目前实体肿瘤免疫治疗的研究热点。通过分子影像方法检测实体肿瘤患者体内PD-1/PD-L1表达情况能够预测肿瘤患者能否从免疫治疗中获益。小分子多肽抑制剂具有相对分子质量低、在肿瘤微环境中扩散速度快、分布均匀、容易到达实体肿瘤深部等显著优势。通过放射性核素标记小分子多肽抑制剂的分子探针PET显像,能够非侵入性、实时、定量地检测肿瘤患者体内PD-1/PD-L1表达,有望为患者筛选、疗效监测、治疗方案优化、预后评估提供新的检测手段。
Immunosuppressant targeting programmed death protein-1 and its ligand(PD-1/PD-L1)is a hot topic in solid tumor immunotherapy.Detection of PD-1/PD-L1 expression in solid tumor patients by molecular imaging can predict whether tumor patients can benefit from immunotherapy.Small molecular polypeptide inhibitors have the advantages of low molecular weight,fast diffusion in tumor microenvironment,uniform distribution and easy access to the deep part of solid tumor.Non-invasive,real-time and quantitative detection of PD-1/PD-L1 expression in tumor patients can be performed by radionuclide labeled small molecular polypeptide inhibitor molecular probe PET imaging.It is expected to provide new detection methods for patient screening,efficacy monitoring,treatment plan optimization and prognosis evaluation.
作者
蒋金泉
刘特立
夏雷
朱华
杨志
Jiang Jinquan;Liu Teli;Xia Lei;Zhu Hua;Yang Zhi(Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education),Department of Nuclear Medicine,Peking University Cancer Hospital&Institute,Beijing 100142,China)
出处
《国际肿瘤学杂志》
CAS
2019年第8期449-452,共4页
Journal of International Oncology
基金
国家自然科学基金(81401467、81671733)。
